Kailera Therapeutics, Inc.
KLRA$3.07B
Mid CapNASDAQBiotechnology🇺🇸North America145 employees
Drugs in Pipeline
3
Phase 3 Programs
2
Upcoming Catalysts
0
Next Catalyst
None scheduled
Market Overview
Stock performance and key metrics
KLRA News
Catalyst Timeline
0 upcoming, 1 past
No catalysts found.
Drug Pipeline
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
KAI-9531 | Phase 3 | Obesity With Diabetes | - | - |
Semaglutide | Phase 3 | Obesity | - | - |
KAI-7535 | Phase 2 | Obesity | - | - |
Market-Implied Move
Regulatory Approvals
Get Catalyst Alerts
Receive weekly digests of upcoming catalysts
Data is aggregated from public sources (FDA, SEC, ClinicalTrials.gov). While we strive for accuracy, information may be incomplete, delayed, or contain errors. Terms apply